Prospective outcome analysis of multiple sclerosis cases reveals candidate prognostic cerebrospinal fluid markers

Background Predicting the long-term disability outcomes of multiple sclerosis (MS) cases is challenging. Objective We prospectively analysed our previous MS cohort with initial cerebrospinal fluid (CSF) proteomics data to reveal disability markers after 8.2±2.2 years of follow-up. Methods Patients with regular follow-up visits were assigned into two groups: those with an age-related MS severity (ARMSS) score ≥5 (unfavourable course group, N = 27) and ARMSS score <5 (favourable course group, N = 67). A machine learning-based algorithm was applied to reveal candidate poor prognosis-associated initial CSF proteins, which were measured in an independent MS cohort (verification group, N = 40) by ELISA. Additionally, the correlation of initial clinical and radiological parameters with long-term disability was analysed. Results CSF alpha-2-macroglobulin (P = 0.0015), apo-A1 (P = 0.0016), and haptoglobin (P = 0.0003) protein levels, as well as cerebral lesion load (>9 lesions) on magnetic resonance imaging, gait disturbance (P = 0.04), and bladder/bowel symptoms (P = 0.01) were significantly higher in the unfavourable course group than in the favourable course group. Optic nerve involvement evident on initial magnetic resonance imaging (P = 0.002) and optic neuritis (P = 0.01) were more frequent in the favourable course group. Conclusion The herein identified initial CSF protein levels, in addition to the clinical and radiological parameters at disease onset, have predictive value for long-term disability in MS cases.

[1]  O. Ciccarelli,et al.  Association of Slowly Expanding Lesions on MRI With Disability in People With Secondary Progressive Multiple Sclerosis , 2022, Neurology.

[2]  D. Conen,et al.  Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study , 2022, The Lancet Neurology.

[3]  D. Goodin,et al.  Spinal Cord Atrophy Predicts Progressive Disease in Relapsing Multiple Sclerosis , 2021, Annals of neurology.

[4]  S. Gauthier,et al.  Disease correlates of rim lesions on quantitative susceptibility mapping in multiple sclerosis , 2021, Scientific Reports.

[5]  MengJiao Sun,et al.  A candidate biomarker of glial fibrillary acidic protein in CSF and blood in differentiating multiple sclerosis and its subtypes: A systematic review and meta-analysis. , 2021, Multiple sclerosis and related disorders.

[6]  M. Ramanathan,et al.  Apolipoproteins AI and E are associated with neuroaxonal injury to gray matter in multiple sclerosis. , 2020, Multiple sclerosis and related disorders.

[7]  R. Browne,et al.  Cholesterol and neurodegeneration: longitudinal changes in serum cholesterol biomarkers are associated with new lesions and gray matter atrophy in multiple sclerosis over 5 years of follow‐up , 2020, European journal of neurology.

[8]  M. Bijak,et al.  Increased level of fibrinogen chains in the proteome of blood platelets in secondary progressive multiple sclerosis patients , 2019, Journal of cellular and molecular medicine.

[9]  David H. Miller,et al.  Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria , 2017, The Lancet Neurology.

[10]  M. Greenwood,et al.  New Multiple Sclerosis Disease Severity Scale Predicts Future Accumulation of Disability , 2017, Front. Neurol..

[11]  H. Ullum,et al.  The Multiple Sclerosis Genomic Map: Role of peripheral immune cells and resident microglia in susceptibility , 2017, bioRxiv.

[12]  M. Ban,et al.  Age Related Multiple Sclerosis Severity Score: Disability ranked by age , 2017, Multiple sclerosis.

[13]  O. U. Sezerman,et al.  CSF Proteomics Identifies Specific and Shared Pathways for Multiple Sclerosis Clinical Subtypes , 2015, PloS one.

[14]  J. Tenorio-Laranga,et al.  Alteration of prolyl oligopeptidase and activated α-2-macroglobulin in multiple sclerosis subtypes and in the clinically isolated syndrome. , 2013, Biochemical pharmacology.

[15]  Yih-Ru Wu,et al.  Analyses of haptoglobin level in the cerebrospinal fluid and serum of patients with neuromyelitis optica and multiple sclerosis. , 2013, Clinica chimica acta; international journal of clinical chemistry.

[16]  Selen Bozkurt,et al.  Application of data mining techniques for detecting asymptomatic carotid artery stenosis , 2011, 2011 4th International Conference on Biomedical Engineering and Informatics (BMEI).

[17]  Jeffrey A. Cohen,et al.  Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria , 2011, Annals of neurology.

[18]  C. Polman,et al.  Clinico-pathological evidence that axonal loss underlies disability in progressive multiple sclerosis , 2010, Multiple sclerosis.

[19]  S. Reingold,et al.  Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria” , 2005, Annals of neurology.

[20]  Alireza Minagar,et al.  Blood-brain barrier disruption in multiple sclerosis , 2003, Multiple sclerosis.

[21]  P. Sundström,et al.  Native and transformed α2‐macroglobulin in plasma from patients with multiple sclerosis , 2003, Acta neurologica Scandinavica.

[22]  W. Brück,et al.  Oligodendrocyte injury in multiple sclerosis: a role for p53 , 2003, Journal of neurochemistry.

[23]  S. Lim,et al.  Role of haptoglobin in free hemoglobin metabolism , 2001, Redox report : communications in free radical research.

[24]  N. Hyka,et al.  Articles on similar topics can be found in the following Blood collections , 2013 .

[25]  Timothy J. Hohman,et al.  Alpha-2 macroglobulin in Alzheimer’s disease: a marker of neuronal injury through the RCAN1 pathway , 2017, Molecular Psychiatry.

[26]  W. Cendrowski,et al.  [Haptoglobin levels in the serum and the cerebrospinal fluid patients with multiple sclerosis]. , 1978, Neurologia i Neurochirurgia Polska.

[27]  John H. Holland,et al.  Adaptation in Natural and Artificial Systems: An Introductory Analysis with Applications to Biology, Control, and Artificial Intelligence , 1992 .